blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3244896

EP3244896 - METHODS FOR TREATING PULMONARY HYPERTENSION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.04.2025
Database last updated on 21.03.2026
FormerThe patent has been granted
Status updated on  10.05.2024
FormerGrant of patent is intended
Status updated on  04.01.2024
FormerExamination is in progress
Status updated on  19.11.2019
FormerRequest for examination was made
Status updated on  20.10.2017
FormerThe international publication has been made
Status updated on  19.07.2017
Most recent event   Tooltip23.01.2026Lapse of the patent in a contracting state
New state(s): IE		published on 25.02.2026  [2026/09]
Applicant(s)For all designated states
Reviva Pharmaceuticals, Inc.
3900 Freedom Circle, Suite 101
Santa Clara, CA 95054 / US
[2017/47]
Inventor(s)01 / BHAT, Laxminarayan
3900 Freedom Circle Suite 101
Santa Clara, California 95054 / US
02 / CANTILLON, Marc
3900 Freedom Circle Suite 101
Santa Clara, California 95054 / US
03 / WALLIS, Ellen M.
3900 Freedom Circle Suite 101
Santa Clara, California 95054 / US
04 / BHAT, Seema Rani
3900 Freedom Circle Suite 101
Santa Clara, California 95054 / US
 [2017/47]
Representative(s)Dragotti & Associati S.P.A., et al
Via Nino Bixio, 7
20129 Milano / IT
[N/P]
Former [2024/24]Dragotti & Associati S.R.L., et al
Via Nino Bixio, 7
20129 Milano / IT
Former [2017/47]Pistolesi, Roberto, et al
Dragotti & Associati Srl
Via Nino Bixio, 7
20129 Milano / IT
Application number, filing date16737674.811.01.2016
[2017/47]
WO2016US12873
Priority number, dateUS201562102470P12.01.2015         Original published format: US 201562102470 P
[2017/47]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016115039
Date:21.07.2016
Language:EN
[2016/29]
Type: A1 Application with search report 
No.:EP3244896
Date:22.11.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 21.07.2016 takes the place of the publication of the European patent application.
[2017/47]
Type: B1 Patent specification 
No.:EP3244896
Date:12.06.2024
Language:EN
[2024/24]
Search report(s)International search report - published on:US21.07.2016
(Supplementary) European search report - dispatched on:EP27.07.2018
ClassificationIPC:A61K31/538, A61P25/24, A61P25/22
[2018/35]
CPC:
A61K31/538 (EP,US); A61P25/22 (EP,US); A61P25/24 (EP,US);
A61P9/12 (EP,US)
Former IPC [2017/47]A61K31/538
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/47]  
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:VERFAHREN ZUR BEHANDLUNG VON PULMONALER HYPERTONIE[2017/47]
English:METHODS FOR TREATING PULMONARY HYPERTENSION[2017/47]
French:MÉTHODES DE TRAITEMENT DE L'HYPERTENSION PULMONAIRE[2017/47]
Entry into regional phase04.08.2017National basic fee paid 
04.08.2017Search fee paid 
04.08.2017Designation fee(s) paid 
04.08.2017Examination fee paid 
Examination procedure04.08.2017Examination requested  [2017/47]
04.08.2017Date on which the examining division has become responsible
14.02.2019Amendment by applicant (claims and/or description)
22.11.2019Despatch of a communication from the examining division (Time limit: M06)
25.06.2020Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
17.08.2020Reply to a communication from the examining division
05.01.2024Communication of intention to grant the patent
30.04.2024Fee for grant paid
30.04.2024Fee for publishing/printing paid
30.04.2024Receipt of the translation of the claim(s)
Opposition(s)13.03.2025No opposition filed within time limit [2025/21]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
17.08.2020Request for further processing filed
17.08.2020Full payment received (date of receipt of payment)
Request granted
26.08.2020Decision despatched
Fees paidRenewal fee
29.01.2018Renewal fee patent year 03
28.01.2019Renewal fee patent year 04
27.07.2020Renewal fee patent year 05
22.06.2021Renewal fee patent year 06
24.01.2022Renewal fee patent year 07
24.01.2023Renewal fee patent year 08
23.01.2024Renewal fee patent year 09
Penalty fee
Additional fee for renewal fee
31.01.202005   M06   Fee paid on   27.07.2020
31.01.202106   M06   Fee paid on   22.06.2021
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCZ12.06.2024
ES12.06.2024
HR12.06.2024
MC12.06.2024
PL12.06.2024
SK12.06.2024
SM12.06.2024
NO12.09.2024
RS12.09.2024
GR13.09.2024
IS12.10.2024
IE11.01.2025
[2026/09]
Former [2025/43]CZ12.06.2024
ES12.06.2024
HR12.06.2024
MC12.06.2024
PL12.06.2024
SK12.06.2024
SM12.06.2024
NO12.09.2024
RS12.09.2024
GR13.09.2024
IS12.10.2024
Former [2025/10]CZ12.06.2024
ES12.06.2024
HR12.06.2024
PL12.06.2024
SK12.06.2024
SM12.06.2024
NO12.09.2024
RS12.09.2024
GR13.09.2024
IS12.10.2024
Former [2025/09]ES12.06.2024
HR12.06.2024
PL12.06.2024
NO12.09.2024
RS12.09.2024
GR13.09.2024
IS12.10.2024
Former [2025/08]ES12.06.2024
HR12.06.2024
PL12.06.2024
NO12.09.2024
RS12.09.2024
GR13.09.2024
Former [2024/49]ES12.06.2024
HR12.06.2024
NO12.09.2024
RS12.09.2024
GR13.09.2024
Former [2024/48]ES12.06.2024
HR12.06.2024
NO12.09.2024
GR13.09.2024
Former [2024/47]HR12.06.2024
NO12.09.2024
GR13.09.2024
Former [2024/46]HR12.06.2024
NO12.09.2024
Documents cited:Search[Y] US2010216783  (BHAT LAXMINARAYAN et al.) [Y] 1-15 * example - *
 [Y] US2009298819  (BHAT LAXMINARAYAN et al.) [Y] 1-15 * figure - *
 [Y] WO2008047883  (OTSUKA PHARMA CO LTD et al.) [Y] 1-15 * page 282; table 117 *
 [Y] WO2006072608  (UNIV SIENA et al.) [Y] 1-15 * page 79 - page 80 *
 [Y] WO2004046124  (GLAXO GROUP LTD et al.) [Y] 1-15 * claim - *
 [YP] WO2015157451  (REVIVA PHARMACEUTICALS INC et al.) [YP] 1-15 * claim - *
 [YP] WO2015131856  (SHANGHAI INST MATERIA MEDICA et al.) [YP] 1-15 * claim - *
 [Y]   MARCOS E ET AL: "SEROTONIN TRANSPORTER INHIBITORS PROTECT AGAINST HYPOXIC PULMONARY HYPERTENSION", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, AMERICAN LUNG ASSOCIATION, NEW YORK, NY, US, vol. 168, no. 4, 15 August 2003 (2003-08-15), pages 487 - 493, XP008033559, ISSN: 1073-449X, DOI: 10.1164/RCCM.200210-1212OC [Y] 1-15 * figure 2 *

DOI:   http://dx.doi.org/10.1164/rccm.200210-1212OC
 [Y]   E HIRONAKA: "Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats", CARDIOVASCULAR RESEARCH, vol. 60, no. 3, 1 December 2003 (2003-12-01), GB, pages 692 - 699, XP055400350, ISSN: 0008-6363, DOI: 10.1016/j.cardiores.2003.09.023 [Y] 1-15 * figure 1 *

DOI:   http://dx.doi.org/10.1016/j.cardiores.2003.09.023
 [Y]   TOMI M ET AL: "Pharmacological evaluation of selected arylpiperazines with atypical antipsychotic potential", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 14, no. 16, 16 August 2004 (2004-08-16), pages 4263 - 4266, XP002690224, ISSN: 0960-894X, [retrieved on 20040626], DOI: 10.1016/J.BMCL.2004.06.005 [Y] 1-15 * table 1 *

DOI:   http://dx.doi.org/10.1016/j.bmcl.2004.06.005
 [YP]   ZHANG ERQUAN ET AL: "Sarpogrelate hydrochloride, a serotonin 5HT2A receptor antagonist, ameliorates the development of chronic hypoxic pulmonary hypertension in rats", JOURNAL OF ANESTHESIA, JAPAN SOCIETY OF ANESTHESIOLOGY, TOKYO, JP, vol. 29, no. 5, 1 May 2015 (2015-05-01), pages 715 - 723, XP035601810, ISSN: 0913-8668, [retrieved on 20150501], DOI: 10.1007/S00540-015-2015-Y [YP] 1-15 * page 719, paragraph l * * figure 5 *

DOI:   http://dx.doi.org/10.1007/s00540-015-2015-y
International search[A] US2008312249  (CHEN ING-JUN et al.) [A] 1, 2, 5, 9-18 * entire document *
 [A] US4613598  (FUKAMI HARUKAZU et al.) [A] 1, 2, 5, 9-18 * entire document *
by applicantUS2010216783
 US2009298819
 WO2008047883
 WO2006072608
 WO2004046124
 US8188076
 US3845770
 US3916899
 US5698155
 US5112598
 US5556611
   ESTEVE ET AL., CELL BIOCHEM BIOPHYS, 2007
   DEMPSIEMACLEAN, BRIT J PHARMACOL, 2008
   DUMITRASCU ET AL., EUR RESPIR J, 2011
   EDDAHIBI ET AL., J CLIN INVEST, 2001
   HIRONAKA ET AL., CARDIOVASC RES, 2003
   MORCROFT ET AL., J PHARMACOL EXP THER, 2005
   COGOLLUDO ET AL., CIRC RES, 2006
   WELSH ET AL., AM J RESPIR CRIT CARE MED, 2004
   LAUNAY ET AL., NAT MED, 2002
   PROVASNIK ET AL., J PHARMACOL EXP THER, 2010
   DUMITRASCU ET AL., EUR RESPIR, 2011
   MARCOS ET AL., AM J RESPIR CRIT CARE MED., vol. 168, no. 4, 15 August 2003 (2003-08-15), pages 487 - 93
   HIRONAKA ET AL., CARDIOVASC RES., vol. 60, no. 3, 1 December 2003 (2003-12-01), pages 692 - 9
   TOMIC ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, no. 16, August 2004 (2004-08-01), pages 4263 - 4266
   SEFTON, CRC CRIT. REF BIOMED. ENG., vol. 14, 1987, pages 201
   SAUDEKET, N. ENGL. J. MED., vol. 321, 1989, pages 574
   GOODSON, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, vol. 2, 1984, pages 115 - 138
   RANGERPEPPAS: "J. Macromol. Sci. Rev. Macromol Chem.", vol. 23, 1983, pages: 61
   LEVY ET AL., SCIENCE, vol. 228, 1985, pages 190
   DURING ET AL., ANN. NEUROL., vol. 25, 1989, pages 351
   HOWARD ET AL., J. NEUROSURG., vol. 71, 1989, pages 105
   BAMBA ET AL., INT. J. PHARM., vol. 2, 1979, pages 307
   VERMA ET AL., DRUG DEV. IND. PHARM., vol. 26, 2000, pages 695 - 708
   LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533
   HOYER, D. ET AL., EUR. JOURNAL PHARMACOL., vol. 118, 1985, pages 13 - 23
   JARVIS, K. R. ET AL., JOURNAL OF RECEPTOR RESEARCH, vol. 13, no. 1-4, 1993, pages 573 - 590
   GUNDLACH, A. L. ET AL., LIFE SCIENCES, vol. 35, 1984, pages 1981 - 1988
   SCHOEFFTER, P.HOYER, D., NAUNYN-SCHMIEDEBERG'S ARCH. PHARMAC., vol. 340, 1989, pages 135 - 138
   LEYSEN, J. E. ET AL., MOL. PHARMACOL., vol. 21, 1982, pages 301 - 314
   MARTIN, G. R.HUMPHREY, P. P. A., NEUROPHARMACOL., vol. 33, no. 3/4, 1994, pages 261 - 273
   GONZALO, R. ET AL., BR. J. PHARMACOL., vol. 148, 2006, pages 1133 - 1143
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.